☆ 4.7 Article

Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study

JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Serum Alpha and Beta-CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor

Gabriel Garate et al.

Summary: This study aimed to analyze the changes in alpha and beta-CGRP levels during CGRP monoclonal antibodies treatment in patients with chronic migraine. Blood samples were collected from patients with chronic migraine and healthy controls, and the levels of alpha and beta-CGRP were measured using ELISA. The results showed that alpha-CGRP levels significantly decreased during mAb treatment and the decrease was correlated with a reduction in migraine days. Beta-CGRP levels did not change during treatment. These findings support the role of alpha-CGRP as a biomarker for chronic migraine.

ANNALS OF NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study

Fabrizio Vernieri et al.

Summary: This study evaluated the 1-year effectiveness and tolerability of galcanezumab in real-life treatment of high-frequency episodic and chronic migraine. The results showed that a majority of patients experienced a significant reduction in monthly migraine days for at least 9 months. Triptan response, lower body mass index, and an early reduction in migraine days were identified as predictive factors for a persistent response.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study

Hyoung Cheol Lee et al.

Summary: This study identified everyday headache, presence of depression, and absence of accompanying symptoms as significant predictors of a poor response to galcanezumab treatment in patients with chronic migraine.

NEUROLOGICAL SCIENCES (2023)

Add to Collection

Article Clinical Neurology

Late Response to Anti-CGRP Monoclonal Antibodies in Migraine

Piero Barbanti et al.

Summary: In a multicenter study assessing the use of anti-CGRP mAbs in patients with high-frequency or chronic migraine, it was found that half of the nonresponders at 12 weeks actually responded later. Efficacy of the treatment should be evaluated at 24 weeks and treatment duration extended beyond 12 months.

NEUROLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Migraine

Michel D. Ferrari et al.

Summary: This paper summarizes the epidemiology, pathophysiology, diagnosis and treatment of migraine, and discusses quality of life issues faced by patients with migraine and future research avenues. It provides an overview of the etiology of migraine, various treatment options, and the emergence of new treatment targets and therapies.

NATURE REVIEWS DISEASE PRIMERS (2022)

Add to Collection

Article Clinical Neurology

Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients

Soonwook Kwon et al.

Summary: This study provides real-world data on the effectiveness of an anti-calcitonin gene-related peptide monoclonal antibody for treating migraine in Korean patients. The results show that the treatment is effective and safe, with a higher response rate observed in difficult-to-treat patients compared to clinical trials.

CEPHALALGIA (2022)

Add to Collection

Article Clinical Neurology

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions

Linda Al-Hassany et al.

Summary: Migraine is the second most disabling disorder worldwide, and the pharmacology and clinical effects of CGRP-targeted drugs are not fully understood. Factors such as sex, body-mass index, age, and ethnic background may affect the pharmacokinetics of these treatments, particularly Gepants. Patient characteristics may play a more prominent role in the management of migraine as more is learned about CGRP-targeted therapies.

LANCET NEUROLOGY (2022)

Add to Collection

Review Clinical Neurology

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update

Simona Sacco et al.

Summary: This guideline evaluated the effectiveness and safety of monoclonal antibodies targeting the CGRP pathway for migraine prevention through systematic review and literature analysis, and provided updated treatment recommendations.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Letter Clinical Neurology

Editors' Note: Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study

Aravind Ganesh et al.

NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

Tsubasa Takizawa et al.

Summary: This study evaluated the efficacy and safety of Galcanezumab in Japanese patients with migraines, showing a reduction in monthly migraine days and improvement in migraine-associated symptoms. However, more than 50% of patients still reported premonitory symptoms without subsequent headaches after 3 months of treatment.

BMC NEUROLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

Patricia Pozo-Rosich et al.

Summary: The study demonstrates that once monthly galcanezumab exhibits consistent efficacy throughout the dosing interval among patients with migraine in clinical trials, with no evidence of the drug's effect wearing off at the end of the dosing interval.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Clinical Neurology

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine

Hisaka Igarashi et al.

Summary: The study demonstrated that galcanezumab has a rapid onset and maintenance effect in preventing episodic migraine in Japanese patients, significantly reducing the number of headache days and proportion of patients with migraine compared to placebo. Additionally, the 50% response rate was higher with galcanezumab from week 1 through month 6 of treatment.

JOURNAL OF PAIN RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

Todd J. Schwedt et al.

Summary: In patients who had not previously benefited from multiple migraine preventive treatments, galcanezumab demonstrated significant reduction in migraine headache days starting from the second month of treatment, indicating an early onset of therapeutic effect.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Review Clinical Neurology

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

William Kielbasa et al.

CEPHALALGIA (2019)

Add to Collection

Article Clinical Neurology

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

Peter J. Goadsby et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

Add to Collection

Article Clinical Neurology

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Vladimir Skljarevski et al.

CEPHALALGIA (2018)

Add to Collection

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

Add to Collection

Article Clinical Neurology

Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial

Virginia L. Stauffer et al.

JAMA NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

Stefanie Foerderreuther et al.

JOURNAL OF HEADACHE AND PAIN (2018)

Add to Collection

Article Clinical Neurology

Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study

Holland C. Detke et al.

NEUROLOGY (2018)

Add to Collection

Article Neurosciences

Modulation of CGRP-Induced Light Aversion in Wild-Type Mice by a 5-HT1B/D Agonist

Eric A. Kaiser et al.

JOURNAL OF NEUROSCIENCE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.